EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progress

BACKGROUND: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer that lacks expression of estrogen receptor (ER) and progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2) gene. Chemotherapy remains the standard of care for TNBC treatment,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ruishan, Li, Xiang, Liu, Zhuangkai, Wang, Yuying, Zhang, Hao, Xu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236314/
https://www.ncbi.nlm.nih.gov/pubmed/32477007
http://dx.doi.org/10.1186/s12935-020-01260-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236314/
https://www.ncbi.nlm.nih.gov/pubmed/32477007
http://dx.doi.org/10.1186/s12935-020-01260-5

Ejemplares similares